{
  "label": "clinical_signal_03_ep_015",
  "artifact_type": "signal_episode",
  "artifact_id": "sha256:354f39bfec1a0c86100323c7a427f76857c2be890762578cd0f4f46cabe47110",
  "input_ids": [
    "sha256:b4ba5337b06c8de68ac3315db1a4f6980c5bd48efd529c3914f30297d6afd329",
    "sha256:161174e8025b5c956602ccc4e17b4e677c58230b1b64641f357c400c448b8151"
  ],
  "prompt_id": null,
  "model_config": null,
  "created_at": "2026-02-17T11:54:46.699311",
  "content": "## 2024-06-10 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 215\n- Active: 208\n- Screen Failures Cumulative: 33\n- Withdrawals Cumulative: 7\n\n#### Sites\n- Site 01 Enrolled: 22\n- Site 01 Active: 22\n- Site 01 Statin Concomitant: 5\n- Site 02 Enrolled: 16\n- Site 02 Active: 16\n- Site 02 Statin Concomitant: 4\n- Site 03 Enrolled: 20\n- Site 03 Active: 20\n- Site 03 Statin Concomitant: 5\n- Site 04 Enrolled: 14\n- Site 04 Active: 14\n- Site 04 Statin Concomitant: 3\n- Site 05 Enrolled: 18\n- Site 05 Active: 18\n- Site 05 Statin Concomitant: 5\n- Site 06 Enrolled: 12\n- Site 06 Active: 12\n- Site 06 Statin Concomitant: 3\n- Site 07 Enrolled: 23\n- Site 07 Active: 23\n- Site 07 Statin Concomitant: 7\n- Site 08 Enrolled: 16\n- Site 08 Active: 16\n- Site 08 Statin Concomitant: 4\n- Site 09 Enrolled: 18\n- Site 09 Active: 18\n- Site 09 Statin Concomitant: 4\n- Site 10 Enrolled: 14\n- Site 10 Active: 14\n- Site 10 Statin Concomitant: 4\n- Site 11 Enrolled: 20\n- Site 11 Active: 20\n- Site 11 Statin Concomitant: 5\n- Site 12 Enrolled: 16\n- Site 12 Active: 16\n- Site 12 Statin Concomitant: 4\n\n### Lab Panels\n- Statin Subgroup N: 54\n- Statin Subgroup ALT (U/L) Mean: 62.2\n- Statin Subgroup ALT (U/L) Median: 61.3\n- Statin Subgroup AST (U/L) Mean: 51.0\n- Statin Subgroup AST (U/L) Median: 50.3\n- Statin Subgroup Bilirubin (mg/dL) Mean: 0.89\n- Statin Subgroup Bilirubin (mg/dL) Median: 0.86\n- Statin Subgroup ALP (U/L) Mean: 58.6\n- Statin Subgroup ALP (U/L) Median: 78.4\n- Statin Subgroup Creatinine (mg/dL) Mean: 0.97\n- Statin Subgroup Creatinine (mg/dL) Median: 0.8\n- Statin Subgroup BUN (mg/dL) Mean: 14.8\n- Statin Subgroup BUN (mg/dL) Median: 16.3\n- Statin Subgroup WBC (K) Mean: 6.4\n- Statin Subgroup WBC (K) Median: 7.9\n- Statin Subgroup Platelets (K) Mean: 241\n- Statin Subgroup Platelets (K) Median: 212\n- Non-Statin Subgroup N: 125\n- Non-Statin Subgroup ALT (U/L) Mean: 26.0\n- Non-Statin Subgroup ALT (U/L) Median: 25.2\n- Non-Statin Subgroup AST (U/L) Mean: 22.2\n- Non-Statin Subgroup AST (U/L) Median: 21.0\n- Non-Statin Subgroup Bilirubin (mg/dL) Mean: 0.64\n- Non-Statin Subgroup Bilirubin (mg/dL) Median: 0.59\n- Non-Statin Subgroup ALP (U/L) Mean: 65.4\n- Non-Statin Subgroup ALP (U/L) Median: 71.5\n- Non-Statin Subgroup Creatinine (mg/dL) Mean: 0.86\n- Non-Statin Subgroup Creatinine (mg/dL) Median: 0.86\n- Non-Statin Subgroup BUN (mg/dL) Mean: 12.5\n- Non-Statin Subgroup BUN (mg/dL) Median: 16.1\n- Non-Statin Subgroup WBC (K) Mean: 5.9\n- Non-Statin Subgroup WBC (K) Median: 6.9\n- Non-Statin Subgroup Platelets (K) Mean: 229\n- Non-Statin Subgroup Platelets (K) Median: 227\n\n### Adverse Events\n- AE ID: AE-0050, Description: back pain, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0051, Description: nasopharyngitis, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0052, Description: arthralgia, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n- AE ID: AE-0053, Description: transaminase measurement out of range, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n- AE ID: AE-0054, Description: transaminase measurement out of range, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 52\n- ACE Inhibitor Count: 27\n- Metformin Count: 23\n- PPI Count: 19\n- NSAID Count: 12\n- Other Count: 35\n\n### Protocol Deviations\n- PD ID: PD-031, Description: Dose modification without documented PI approval, Severity: moderate, Site: site_11\n\n### Investigator Notes\n- Study drug accountability reconciled, no discrepancies\n- Central lab results received within 48h turnaround\n- Site 07 ALT re-assay ordered for 8 specimens, calibration offset confirmed\n\n### Events\n- Drug accountability audit at Site 12: no discrepancies\n- IP resupply shipped to Sites 07, 03\n- Site 07 lab re-assay requested for 8 specimens flagged during calibration review\n\n### Notes\n- Week 15: Site 07 re-assay ordered. Statin subgroup hepatic values persist across sites.",
  "metadata": {
    "episode_id": "clinical_signal_03_ep_015",
    "scope_id": "clinical_signal_03",
    "timestamp": "2024-06-10T10:00:00",
    "phase": "early_signal",
    "signal_density": "low",
    "episode_type": "signal",
    "layer_name": "signal_episodes",
    "layer_level": 2,
    "build_fingerprint": {
      "scheme": "synix:build:v1",
      "digest": "724335e48952198659b608a79f591f6985cc457d1b0726c271a193e4d218a284",
      "components": {
        "transform": "f5403588af46952374060f29447e5a7639e5b66fc9aef1799b08473882c4bcbc",
        "inputs": "a94b84fbaca9bd62"
      }
    },
    "transform_fingerprint": {
      "scheme": "synix:transform:v2",
      "digest": "f5403588af46952374060f29447e5a7639e5b66fc9aef1799b08473882c4bcbc",
      "components": {
        "transform_id": "cb4ddfa83a38701b",
        "source": "42e76241d396a578",
        "model": "1e2ccf75e96d7ee7"
      }
    }
  }
}